STX-100 is a humanized monoclonal antibody to integrin αvβ6. It acts by blocking the activation of a key anti-fibrotic cytokine, TGFβ, selectively at sites of tissue injury. It exhibits significant anti-fibrotic activity in preclinical models of lung, kidney, and liver disease.
STX-100 has completed Phase 1 clinical testing and a Phase 2 trial in patients with idiopathic pulmonary fibrosis (IPF) is currently underway at multiple sites in the US. For more information on this clinical trial, please visit ClinicalTrials.gov or CenterWatch.
About fibrosis and organ failure
Fibrosis is wound repair gone bad. It is a consequence of chronic cycles of tissue injury and repair, often playing out over years and decades, leading to the accumulation of scar tissue in affected organs and disruption of normal tissue architecture and function. In short, the organ fails.
Fibrosis is the final common pathway in virtually all forms of chronic organ failure. The cellular and molecular biology of fibrosis is similar across multiple organs and multiple sources of tissue injury. Fibrosis results from the excessive activity of tissue fibroblasts, particularly an activated form called the myofibroblast. Thus, experts believe that agents that attenuate myofibroblast activity, in particular by targeting the critical cytokine TGFβ, ought to slow, stop, or perhaps reverse the progression of fibrosis in affected tissue, thereby preserving organ function and prolonging healthy life.
Stromedix is a company focused on developing novel therapies for fibrosis and organ failure. Stromedix was acquired by Biogen Idec in March 2012 and operates as a wholly owned subsidiary of Biogen Idec in its Cambridge MA facility.